Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings

Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings

Abstract Background Junctional adhesion molecule-A (JAM-A) is an adhesion molecule whose overexpression on breast tumor tissue has been associated with aggressive cancer phenotypes, including human epidermal growth factor receptor-2 (HER2)-positive disease. Since JAM-A has been described to regulate...

Full description

Bibliographic Details
Main Authors: Astrid O. Leech, Sri HariKrishna Vellanki, Emily J. Rutherford, Aoife Keogh, Hanne Jahns, Lance Hudson, Norma O’Donovan, Siham Sabri, Bassam Abdulkarim, Katherine M. Sheehan, Elaine W. Kay, Leonie S. Young, Arnold D. K. Hill, Yvonne E. Smith, Ann M. Hopkins
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Breast Cancer Research
Subjects:
JAM-A
Tight junction
HER2
Breast cancer
Drug resistance
HER2-targeted therapies
Online Access:http://link.springer.com/article/10.1186/s13058-018-1064-1

Internet

http://link.springer.com/article/10.1186/s13058-018-1064-1

Similar Items